The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway.Endothelin is upregulated in hypertension and is a fundamental mediator in patients whose hypertension is difficult-to-control.Hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality. Allschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025Idorsia Ltd (SIX: IDIA) announces that its novel dual endoth ...

Allschwil, Switzerland – August 12, 2025Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nominated TRYVIO™ (aprocitentan) in the category of “Best Pharmaceutical Product” in the 2025 Prix Galien USA awards. The winner will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025. To qualify for the Prix Galien Award, each candidate must be US Food and Drug Administration (FDA) approved ...